Background--We asked whether, after excluding familial hypercholesterolemia, individuals with high low-density lipoprotein cholesterol (LDL-C) or triacylglyceride levels and a family history of the same hyperlipidemia have greater coronary artery disease risk or different lipidomic profiles compared with population-based hyperlipidemias.
H igh levels of low-density lipoprotein cholesterol (LDL-C) and triacylglycerides have been identified as causal risk factors for atherosclerotic cardiovascular disease (ASCVD). 1, 2 These hyperlipidemias may arise through lifestyle factors, but they are also highly heritable. [3] [4] [5] [6] An estimated half of patients with premature coronary artery disease (CAD) have dyslipidemia with a family history of dyslipidemia, most of which are characterized by increases in LDL-C and/or triacylglycerides. 7 Whether dyslipidemias with family history should be diagnosed and managed differently from hyperlipidemias observed in randomly ascertained individuals in the general population is uncertain. Clinical guidelines emphasize their identification but, with the exception of familial hypercholesterolemia (FH), refrain from strong management recommendations. 8, 9 The monogenic FH patients with rare high-impact LDL-C-elevating variants have a higher risk of developing CAD than noncarriers with similar lipid levels. 10 This is potentially related to lifelong exposure to high LDL-C levels and suggests that these individuals may benefit from earlier or more aggressive LDL-C-lowering therapy. In contrast with FH, many other hyperlipidemias with family history appear genetically similar to population-ascertained hyperlipidemias.
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Whether such hyperlipidemias with family history also confer additional elevation in ASCVD risk is not known. Herein, we assess incident ASCVD risk associated with familial aggregation of high LDL-C and triacylglycerides, excluding individuals with FH. We also ask whether their circulating lipid phenotypes are similar compared with population-ascertained hyperlipidemias. Recent technological advancements have allowed replicable and simultaneous quantification of hundreds of lipid species, the main constituents of LDL and triacylglyceride-rich lipoproteins, through lipidomic profiling. 14, 15 We test whether detailed phenotypic differences in lipidomic profiles, which might reflect different pathophysiological features and ASCVD susceptibility, exist between hyperlipidemias with family history and population-ascertained hyperlipidemias. Using a direct infusion platform that combines absolute quantification with high throughput, we were able to overcome problems that have hampered many previous studies. 16 In this study, we first estimated the CAD risk associated with high LDL-C or triacylglyceride levels with family history and population-ascertained hyperlipidemias with similarly high LDL-C or triacylglycerides. Second, we characterized the lipidomic profiles associated with elevated plasma levels of LDL-C and triacylglycerides. Finally, we compared the lipidomic profiles of hyperlipidemias with family history and population-ascertained hyperlipidemias to assess their potential differences.
Materials and Methods

Subjects and Clinical Ascertainment
The Finnish hyperlipidemia families included in this cohort study (74 families, n=1445 individuals with LDL-C and triacylglyceride measures) were identified as part of the EUFAM (European Multicenter Study on Familial Dyslipidemias in Patients With Premature Coronary Heart Disease) project. Initial recruitment aimed to identify families with familial combined hyperlipidemia (at least 2 family members with total cholesterol and/or triacylglycerides ≥90th population percentile) or families with aggregation of low highdensity lipoprotein cholesterol. Classic FH was excluded on the basis of an in-house functional LDL receptor test for the probands and later genotyping of selected Finnish FH mutations in other family members with high LDL-C; further recruitment was not pursued in putative FH pedigrees. 17 For the present study, designation of "high LDL-C with family history" or "high triacylglycerides with family history" was made if at least 2 first-degree relatives had LDL-C or triacylglyceride levels, respectively, that were >90th ageand sex-specific Finnish 1997 population percentiles (Table S1 ) without being affected by diabetes mellitus or other relevant comorbidities ( Figure S1 ). More detailed information is given in Data S1. Individuals from the Finnish National FINRISK study were used as a Finnish population-based comparison group. A total of 19 644 individuals from the FINRISK study 1992 to 2002 cohorts and 755 individuals from EUFAM families were linked with the national hospital discharge and causes-of-death registries. Clinical incident CAD event end points were defined as either myocardial infarction or coronary revascularization (coronary angioplasty or coronary artery bypass grafting).
Clinical Perspective
What Is New?
• Beyond familial hypercholesterolemia, the impact of hyperlipidemic family history on coronary artery disease risk is debated.
• Coronary artery disease risk was comparable in our hyperlipidemic subjects (low-density lipoprotein cholesterol or triacylglycerides >90th population percentile) with family history and subjects with population-ascertained hyperlipidemias.
• The lipidomic profiles of such hyperlipidemias were independent of family history, providing evidence for similar and/or overlapping metabolic pathways.
What Are the Clinical Implications?
• Our results do not support different screening for those with a family history of hyperlipidemia and sporadically discovered hyperlipidemic cases.
CVD was defined as CAD or stroke, excluding subarachnoid hemorrhage. Mean (range) follow-up time from baseline to CAD end point, death, or end of registry follow-up was 16.1 (0.1-20.1) years in EUFAM and 12.6 (0.02-19.0) years in the FINRISK study. More detailed information is given in Data S1. Written informed consent was obtained from all participants, except the 1992 FINRISK study survey, for which verbal informed consent was obtained, as required by legislation and ethics committees at the time. All samples were collected in accordance with the Declaration of Helsinki, and study protocols were approved by the ethics committees of the participating centers (The Hospital District of Helsinki and Uusimaa Coordinating Ethics committees, approval No. 184/ 13/03/00/12). Because of the consent given by the study participants, the data cannot be made publicly available. The data are available through the Institute for Molecular Medicine Finland Data Access Committee for authorized researchers who have an institutional review board/ethics approval and an institutionally approved study plan. For more details, please contact the Institute for Molecular Medicine Finland Data Access Committee (fimm-dac@helsinki.fi).
Lipidomics Measurements
Lipidomic profiling of circulating lipid species was performed for 550 EUFAM family members (all members with available plasma samples) and for 897 individuals from the FINRISK 2012 study cohort, after excluding individuals with predefined comorbidities (Data S1) and individuals known to use lipidlowering medication or sex hormones at the time of the measurements. Mass spectrometry-based lipid analysis was performed at Lipotype GmbH (Dresden, Germany), as described.
14 Plasma and serum lipids were extracted with methyl tert-butyl ether/methanol (7:2, v/v). 18 Samples were analyzed by direct infusion in a QExactive mass spectrometer (Thermo Scientific) equipped with a TriVersa NanoMate ion source (Advion Biosciences). Samples were analyzed in both positive and negative ion modes in a single acquisition. Data were analyzed with in-house-developed lipid identification software based on LipidXplorer. 19, 20 Reproducibility was assessed by the inclusion of reference plasma samples. The median coefficient of variation was <10% across all batches. A total of 151 species were detected in ≥80% of both EUFAM and FINRISK study samples and were included in subsequent analyses. Right-skewed lipidomics measures were natural logarithm transformed before normalization. More detailed information is given in Data S1.
Statistical Analyses
To assess the risk of incident CAD associated with the hyperlipidemias, we used Cox proportional hazards models using age as the time scale, stratified by sex and clustered by family, to estimate hazard ratios (HRs) for incident CAD (or CVD) events, excluding individuals with prevalent CAD (or CVD). Additional models were also adjusted by lipid-lowering medication and smoking. The statistical significance of intercohort differences in HRs was estimated on the basis of an interaction term between hyperlipidemia status and cohort designation. We used linear mixed models to estimate the association between lipidomic measurements and predictors of interest (hyperlipidemia status or continuous lipid measurement), as implemented in MMM (version 1.01). 21 Age, age 2 , and sex were used as additional fixed-effect covariates.
To account for relatedness among individuals, an empirical genetic relationship matrix was included as the covariance structure of a random effect. Statistical significance was evaluated using the Benjamini-Hochberg method at the 5% level to account for multiple comparisons similarly to recent lipidomics studies of CVDs. 22, 23 R (version 3.4.3) was used for data transformations and other analyses. 24 Detailed information is given in Data S1.
Results
Clinical Characteristics and CAD Risk of Individuals With High Levels of LDL-C or Triacylglycerides
We first assessed the risk of developing CAD associated with high levels of LDL-C or triacylglycerides in individuals from the Finnish FINRISK study population survey and in hyperlipidemic families ascertained as part of the EUFAM ( Figure 1 ; Table S2 ; Figure S1A ). Individuals with LDL-C >90th percentile had an increased risk of incident CAD in the FINRISK study population surveys (n=19 644 individuals) compared with other individuals (HR, 1.74; 95% CI, 1.48-2.05) ( Figure 1 ). The members of hyperlipidemic families with high LDL-C had a similar HR for CAD compared with their relatives without high LDL-C in 47 "high LDL-C" families (n=625 individuals) (HR, 1.71; 95% CI, 0.94-3.10). The HRs did not differ between the cohorts (P=0.84). The mean age at incident CAD diagnosis was similar among individuals with high LDL-C in the hyperlipidemic families (62.8 years) and in the population cohort (63.5 years). We also observed increased CAD risk in individuals with high triacylglycerides in the population (HR, 1.38; 95% CI, 1.09-1.75) and a similar HR in 35 "high triacylglyceride" families (n=371 individuals) (HR, 1.35; 95% CI, 0.52-3.51). The HRs did not differ between the cohorts (P=0.82). The results remained similar after adjusting for lipidlowering medication use and smoking ( Figure S2 and Table S3 ) and body mass index (Table S3) . Furthermore, we found no differences between the cohorts in the risk of incident CVD (P=0.42-0.98; Figure S3A and S3B; Table S3 ). Meta-analyses of HRs closely approximated estimates derived from the population cohort. We then characterized the detailed lipidomic profiles of 550 individuals from 73 hyperlipidemic families and 897 individuals from the FINRISK population study (Methods;  Tables S4, S5 and S6) . These included 105 individuals (23%) of 463 family members in 53 high LDL-C families who had LDL-C levels >90th percentile (meanAESD, 5.2AE0.8 mmol/L) and 64 individuals (22%) of 287 family members in 39 high triacylglyceride families who had triacylglycerides >90th percentile (meanAEinterquartile range, 3.6AE1.8 mmol/L). Using similar cutoffs in the population, 56 individuals (6%) and 65 individuals (7%) of 897 were affected by high LDL-C levels (meanAESD, 5.3AE1.1 mmol/L) and high triacylglycerides (meanAEinterquartile range, 3.5AE1.9 mmol/L), respectively. Both high LDL-C and triacylglyceride levels were observed in 31 individuals (6%) in the family cohort and 9 individuals (1%) in the population cohort.
High LDL-C and Lipidomic Profiles
To characterize the lipidomic profiles associated with elevated values of LDL-C, we compared individuals with high LDL-C levels with those without. In the hyperlipidemic families, individuals with a high LDL-C had significantly elevated levels of 99 lipid species spread out across most of the studied lipid classes. Reduced levels among the high LDL-C individuals were observed for 3 lysophospatidylcholine, 2 lysophosphatidylethanolamine, and 1 phosphatidylcholine-ether (PCO) species ( Figure 2A ; Table S7 ). Similar trends were seen in the population cohort, in which the levels of 51 lipid species were elevated among high LDL-C individuals ( Figure 2B ; Table S7 ). The effect estimates correlated strongly across all lipid species between the hyperlipidemic families and the population cohorts (Pearson's r=0.80; Figure 3 ). Furthermore, we observed no significant differences in the effect estimates between the cohorts at the 5% false discovery rate (FDR).
We also studied the association of high LDL-C levels with the degree of saturation of fatty acids in each lipid class. In the hyperlipidemic families, high LDL-C levels were associated with increased saturation of lysophospatidylcholines and ceramides, as well as reduced saturation of lysophosphatidylethanolamines, phosphatidylcholines, PCOs, and phosphatidylinositols (P-value range=0.019-0.0014) ( Figure S4 ). In the population cohort, the trends were similar, although there was an association for increased lysophospatidylcholine Figure 1 . Risk of incident coronary artery disease (CAD) in hyperlipidemias with family history and population-ascertained hyperlipidemias. To assess the risk of incident CAD associated with the hyperlipidemia types, we used Cox proportional hazards models using age as the time scale, stratified by sex and clustered by family, to estimate hazard ratios (HRs) for incident CAD events, excluding individuals with prevalent CAD. Further details on the participants are presented in Table S2 . LDL-C indicates low-density lipoprotein cholesterol; TG, triacylglycerides. saturation only (P=7.2910 À4 ). The effect estimates did not differ significantly between the hyperlipidemic families and the population sample at the 5% FDR. Overall, the lipidomic profiles associated with high LDL-C levels appeared similar in the hyperlipidemic families and the general population.
High Triacylglycerides and Lipidomic Profiles
In the hyperlipidemic families, individuals with high triacylglycerides had elevated levels of 107 lipid species covering all studied lipid classes with the exception of lysophosphatidylethanolamines. In addition, we observed reduced levels of 7 PCO, 2 lysophospatidylcholine, and 1 phosphatidylinositol species ( Figure 4A ; Table S7 ). Similar profiles were seen in the population when comparing individuals with high triacylglycerides with those without, including elevated levels of 108 species and reduced levels of 10 PCO and 1 lysophospatidylcholine species ( Figure 4B ; Table S7 ). The effect estimates correlated highly across all species between the families and the population cohort (Pearson's r=0.96; Figure 3 ). Furthermore, we observed no significant differences in the effect estimates between the cohorts at the 5% FDR. When contrasting the profiles observed for the 2 types of hyperlipidemias, we saw that high triacylglyceride levels were more uniquely reflected in a range of circulating lipid classes, including triacylglycerides, diacylglycerides, phosphatidylethanolamines, phosphatidylcholines, PCOs, and phosphatidylinositols. However, associations with sphingomyelin species appeared more unique to high LDL-C levels.
Next, we studied the association of high triacylglyceride levels with the degree of saturation of fatty acids in each lipid class. In both the hyperlipidemic families and the population, having high triacylglycerides was associated with increased saturation of triacylglycerides, diacylglycerides, affected by high LDL-C levels (n=105) were compared with their unaffected relatives (n=358) in the 53 "high LDL-C" families. B, Individuals affected by high LDL-C (n=56) were compared with other individuals (n=841) in the FINRISK study population cohort. The association of high LDL-C status with the lipid species was estimated using linear mixed models with age, age 2 , and sex as the other fixed-effect covariates. Statistical significance was evaluated using the Benjamini-Hochberg method at a 5% false discovery rate (FDR). The ordering of the lipid species within each class is the same as in Table S7 . Cer indicates ceramide; DG, diacylglyceride; FDR, false discovery rate; LDL-C, low-density lipoprotein cholesterol; LPA, lysophosphatic acid; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; PC, phosphatidylcholine; PCO, phosphatidylcholine-ether; PE, phosphatidylethanolamine; PEO, phosphatidylethanolamine-ether; PI, phosphatidylinositol; CE, cholesteryl ester; SM, sphingomyelin; ST, sterol; TG, triacylglyceride.
lysophospatidylcholines, and cholesteryl esters (CEs) (P-value range=0.0012-5.9910 À11 ) ( Figure S5 ). The effect estimates did not differ significantly between the hyperlipidemic families and the population sample at the 5% FDR. Overall, we observed great similarity in the lipidomic profiles associated with high triacylglycerides in the hyperlipidemic families and in the general population.
Independent Associations of LDL-C and Triacylglyceride Values With the Lipid Species
We then tested if the variation in the lipid species was driven by both LDL-C and triacylglyceride levels or if either was dominating the profiles. For this, we estimated the independent associations of LDL-C and triacylglyceride levels with each lipid species in coadjusted models ( Figure 5 ; Table S7 ). In these analyses, many of the observed associations with LDL-C were greatly diluted in magnitude, most notably for triacylglyceride, diacylglyceride, and phosphatidylcholine species. LDL-C levels remained most strongly associated with CE, sphingomyelin, ceramide, phosphatidylcholine, and PCO species in both cohorts. A total of 83 species in the hyperlipidemic families and 91 species in the population were independently associated with LDL-C at the 5% FDR. In contrast, triacylglycerides remained strongly associated with a wide range of lipid species, including all individual triacylglyceride species, diacylglycerides, phosphatidylcholines, phosphatidylethanolamines, phosphatidylinositols, ceramides, and a subset of CEs in both cohorts. A total of 125 species in the hyperlipidemic families and 124 species in the population were independently associated with triacylglycerides at the 5% FDR. Overall, only 13 species were uniquely associated with LDL-C in either cohort, whereas 42 species were uniquely associated with triacylglycerides ( Figure 6 ).
Discussion
Recent lipidomic approaches have identified several hundreds of different lipid species in the human circulation, some of which could be better prognostic biomarkers for ASCVD than the traditional clinical chemistry measurements. In this study, we used a mass spectrometric lipidomics platform to assess the lipidomic profiles in individuals with high LDL-C and/or triacylglyceride levels. We found that individuals affected by high levels of LDL-C or triacylglycerides had CAD HRs between 1.35 and 1.74 in the family and population cohorts and exhibited distinct lipidomic profiles with clear variation between lipid classes. In total, of 151 lipidomic species, 108 were significantly associated with high LDL-C and 131 with high triacylglyceride levels in at least one cohort. Of these species, 96 were associated with both high LDL-C and triacylglycerides. In addition, we observed highly similar lipidomic profiles between the hyperlipidemias with family history and population-ascertained hyperlipidemias. The present study is the most comprehensive lipidomic profiling of common hyperlipidemias to date. The correlation between the effect estimates observed in the family and population cohorts is presented for high low-density lipoprotein cholesterol (LDL-C) (effect estimates presented in Figure 2 ; A) and for high triacylglycerides (effect estimates presented in Figure 4 ; B). Cer indicates ceramide; DG, diacylglyceride; LDL-C, low-density lipoprotein cholesterol; LPA, lysophosphatic acid; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; PC, phosphatidylcholine; PCO, phosphatidylcholine-ether; PE, phosphatidylethanolamine; PEO, phosphatidylethanolamine-ether; PI, phosphatidylinositol; CE, cholesteryl ester; SM, sphingomyelin; ST, sterol; TG, triacylglyceride.
These findings allow us to draw several conclusions. First, the CAD risks are highly similar regardless of whether hyperlipidemic individuals were identified from families with a high prevalence of similar hyperlipidemia or from the general population. Earlier studies have found higher CAD risk in relatives of familial combined hyperlipidemia probands compared with spouses. [25] [26] [27] Our study, however, compares the estimates between family members and individuals with similar lipid levels from the population to quantify the effect of familiality. We also studied the risk associated with elevated LDL-C and triacylglycerides separately. Our estimates for CAD risk caused by high LDL-C with family history are lower than typically reported for monogenic FH, despite comparable differences in LDL-C levels. 10, 28, 29 In the present study, we excluded probands with monogenic FH based on a functional LDL receptor test and genetic testing in the families. Excepting monogenic FH, hyperlipidemias with family history of high LDL-C and/or triacylglyceride levels have been reported to be highly polygenic. [11] [12] [13] 30 The pleiotropic effects of diverse genes and pathways, in contrast with the single affected pathway in monogenic FH, may partly explain why we did not observe increased CAD risk caused by familiality in our study. Second, to more deeply characterize potential differences between hyperlipidemias with family history and populationascertained hyperlipidemias, we performed precise phenotyping of circulating lipid species known to be associated with ASCVD risk. 22, 23, 31 Individual lipid species, including sphingolipids, glycerophospholipids, glycerolipids, and CEs, have previously been associated with ASCVD incidence or event risk over traditional risk factors. 22, 23, 31, 32 Major differences in the metabolic pathways underlying different types of hyperlipidemias would thus be expected to be reflected in different lipidomic profiles. As an example, individuals with low highdensity lipoprotein cholesterol levels have previously been shown to have low phosphatidylethanolamine-plasmalogen levels in high-density lipoprotein particles, a putative marker of high-density lipoprotein antioxidative capacity. 33 Herein, in contrast, we observed similar profiles in hyperlipidemias with family history and population-ascertained hyperlipidemias, highlighting the biochemical similarity of the conditions. We started by characterizing the lipid profiles associated with high LDL-C and triacylglyceride levels. Many of the associations were not specific to LDL-C but were rather caused by combined dyslipidemia. LDL particles are generated in circulation as downstream metabolic products from the triacylglyceride-rich lipoproteins and their postlipolytic remnants by the action of 2 lipases, lipoprotein lipase and hepatic lipase. 34, 35 A proportion of the core lipids, especially cholesterol esters, and the particle surface phospholipids thus remains in the generated LDL particles. Elevated triacylglyceride levels were associated with differences in the levels of lipid species across most of the studied classes. More important, most of these associations appeared to be independent of LDL-C levels. Among the lipid species that were strongly correlated with high triacylglycerides after correction for LDL-C levels were several species that have previously been associated with risk of ASCVD. 22, 23, 31 These include the species CE(14:0), CE ( Effect estimates for LDL-C and triacylglycerides were derived from linear mixed models with the lipid species as outcomes and LDL-C, log (triacylglycerides), age, age 2 , and sex as fixed-effect covariates. The effect estimates were derived separately in the hyperlipidemic families (n=550 individuals; A) and the FINRISK study population cohort (n=897 individuals; B). Effect estimates are presented for LDL-C in orange and triacylglycerides in purple. Statistical significance was evaluated using the Benjamini-Hochberg method at a 5% false discovery rate (FDR). The ordering of the lipid species within each class is the same as in Table S7 . Cer indicates ceramide; DG, diacylglyceride; FDR, false discovery rate; LDL-C, low-density lipoprotein cholesterol; LPA, lysophosphatic acid; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; PC, phosphatidylcholine; PCO, phosphatidylcholine-ether; PE, phosphatidylethanolamine; PEO, phosphatidylethanolamine-ether; PI, phosphatidylinositol; CE, cholesteryl ester; SM, sphingomyelin; ST, sterol; TG, triacylglyceride.
(50:2), triacylglyceride(50:3), triacylglyceride(52:2), triacylglyceride(52:3), triacylglyceride(52:5), triacylglyceride(56:5), triacylglyceride(56:6), ceramide(42:1;2), and ceramide (42:2;2). Furthermore, high triacylglycerides were associated with increased saturation of fatty acids in the triacylglyceride, diacylglyceride, CE, and lysophospatidylcholine classes. Such differences in the relative fatty acid concentrations can be partly related to dietary intake and reflected in liver-derived very low-density lipoprotein particles, but they are also influenced by endogenous metabolism. 38 Overall, a larger proportion of the lipid species previously linked with increased ASCVD risk was more strongly associated with elevated triacylglycerides rather than with elevated LDL-C. This suggests that the levels of these lipid biomarkers are more closely linked with circulating triacylglyceride-rich lipoprotein metabolism than with LDLs. Third, several lipid species, such as specific CEs, ceramides, and PCOs, remained independently associated with both elevated LDL-C and triacylglycerides. Among these species, the ceramides ceramide(42:1;2) (presumably ceramide[d18:1/24:0]) and ceramide(42:2;2) (presumably ceramide[d18:1/24:1]), the sterol esters CE(16:1) and CE(18:0), and the sphingomyelin(34:1;2) may have added value in ASCVD prediction over traditional lipid measurements. 22, 23, 31 Plasma ceramides have been reported to be independent predictors of cardiovascular events in addition to LDL-C in the population and in patients with CAD. 31, 39, 40 Both LDL-C and triacylglycerides remained independently associated with all 4 ceramides quantified in our study, and LDL-C was additionally associated with increased saturation of ceramides. Unlike most CE species, CE(16:1) was more strongly associated with the concentration of triacylglycerides than with LDL-C in our study. Sphingomyelin(34:1;2) was the only sphingomyelin species that was negatively associated with triacylglycerides; and this association became evident only after adjusting for LDL-C levels. In addition, some species, such as ceramide (42:1;2) and triacylglyceride(56:6), which were positively associated with hyperlipidemias in our sample, have previously been reported to be associated with decreased risk of ASCVD events. 23, 31 These coassociations and discordances between reported associations might explain why some lipid species can improve risk prediction. Consequently, there is an urgent need for a better understanding of the potential underlying signaling and metabolic pathways. Finally, the lipidomic profiles associated with high LDL-C or triacylglyceride levels were comparable between hyperlipidemias with family history and population-ascertained hyperlipidemias. We observed no differences in either the levels of individual lipid species or the saturation of fatty acids within lipid classes. Our findings are in line with a pediatric study of hypercholesterolemia, in which similar nuclear magnetic resonance metabolite profiles (including lipoprotein parameters and circulating fatty acids) were seen for FH and for continuous LDL-C measures in healthy children. 41 These results support the hypothesis that hyperlipidemias with family history and population-ascertained hyperlipidemias have similar, overlapping, and heterogeneous pathophysiological features. Our results are also reassuring for studies that combine familial and population-based hyperlipidemic samples to increase statistical power. Although we present the most comprehensive characterization of CAD risk and circulating lipid species in common hyperlipidemias with family history to date, our study has limitations. Although we were unable to observe significant differences in CAD risk caused by hyperlipidemic family history, the large CIs in the family samples do not preclude their possibility. Careful exclusion of individuals with comorbidities or using lipid-lowering medication reduced our sample size but enabled more robust analyses. We could not perform detailed analyses on individuals with FH as the original study protocol led to their exclusion from further ascertainment. Clinical ascertainment was based on 90th population lipid percentiles; different cutoffs have also been used in other family studies. Some of the individuals surveyed in population cohorts might, in fact, have a family history of hyperlipidemia, including FH, as we could not fully rule out such cases. It is also unclear how well our results can be generalized to other populations than Finns. The field of lipidomics is still relatively young, and concerns have been raised about the replicability of individual lipidomics platforms. The platform used herein overcomes these problems by using direct infusion mass spectrometry for high-throughput screening studies. The similarity of lipidomic profiles between the 2 independent cohorts also supports the replicability of the platform. Furthermore, the lipid species included in our analyses are heritable and associated with both known and novel genetic lipid loci with similar effect sizes in the 2 cohorts. 42 We excluded poorly captured lipid species from the analyses; future advances in lipidomics technology might enable their detection. The blood samples from the hyperlipidemic families were obtained after overnight fasting, whereas participants in the FINRISK population study were advised to fast for 4 hours before the examination and avoid heavy meals earlier during the day. In this light, the similarity of lipidomic profiles between the cohorts becomes even more striking. Moreover, recent recommendations support routine use of nonfasting blood samples for the assessment of plasma lipid profiles.
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In conclusion, our results highlight the similarity between hyperlipidemias with family history and population-based hyperlipidemias in terms of both CAD risk and detailed lipidomic profiles. Except for FH, our results do not support different screening for sporadically discovered cases and those with a family history of hyperlipidemia. Additional work is needed to confirm the validity of this hypothesis in clinical settings. 
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The probands had premature CAD and high levels of total cholesterol, TGs, or both (≥ 90
th Finnish age-7 and sex-specific population percentile), or low HDL-C levels (≤ 10 th percentile). Initial recruitment 8 aimed to identify families with Familial Combined Hyperlipidemia (elevation of TC and/or TGs in at 9 least two family members including the proband) or families with aggregation of low HDL-C. To 10 exclude families with classic familial hypercholesterolemia (FH), probands were screened with an in-11 house functional low-density lipoprotein receptor (LDLR) test similar to a test developed by Cuthbert 12 and colleagues; further ascertainment of these families not pursued. 3 Founder mutations in LDLR have 13 been estimated to explain most (approximately 80%) of FH cases in Finland. 4 Genotyping and 14 imputation did not identify such FH mutations in the members of the remaining families. 5 
15
For the present study, designation of "high LDL-C with family history" or "high TGs with 16 family history" was made if at least two first-degree relatives of each other had LDL-C or TG levels, 17
respectively, that were > 90 th age-and sex-specific Finnish 1997 population percentiles (Supplemental 18 Table 1 ). All other relatives meeting the same lipid criteria within the pedigrees were also classified as 19 affected by the same type of hyperlipidemia with family history. A pedigree was designated as being 20 characterized by both types of hyperlipidemias if the criteria for both designations were simultaneously 21 fulfilled (Supplemental Figure 1) . Individuals with known diabetes, hepatic or renal disease, hypo-or 22 hyperthyroidism, pregnancy, or malignancies did not contribute to establishing family history of 23 hyperlipidemia and were excluded from all analyses. 19,644 individuals) without CAD at baseline and who passed exclusion criteria were used to study the 5 incidence of coronary artery disease associated with hyperlipidemias, and samples from the FINRISK 6 2012 cohort underwent lipidomic profiling (n = 1,141 individuals, 897 of whom passed exclusion 7 criteria). Individuals with known diabetes, pregnancy or cancer were excluded from the analyses. 8
Individuals in all FINRISK cohorts were classified as being affected or unaffected by high LDL-C and 9
high TGs based on the same lipid thresholds as in the EUFAM study. 10
For the EUFAM families, venous serum samples were obtained after an overnight fast and 11 measurements were obtained as described. 5 Participants in the FINRISK population study were advised 12 to fast for four hours before the examination and avoid heavy meals earlier during the day, and 13 measurements were obtained from plasma samples as described.
2 In addition to those with chronic 14 diseases and pregnancy, individuals known to use lipid-lowering or estrogen medication were excluded 15 from the lipidomic analyses. 16
Registry data 17
Tracking of incident CAD and CVD diagnoses was based on the National Finnish Hospital Discharge 18
Register and the National Causes-of-Death Register, whose diagnoses have been previously validated. 
Lipidomics measurements 4
Lipidomics measurements were performed for the EUFAM family samples in two batches (228 and 322 5 individuals), and for the FINRISK population samples in a single batch. Plasma and serum lipids were 6 extracted with methyl tert-butyl ether/methanol (7:2, V:V) as in Matyash et al. 9 Plasma was diluted 50-7 fold with 150 mM ammonium bicarbonate (in water). For lipid extraction, an equivalent of 1 µL of 8 undiluted plasma was used. Internal standards were pre-mixed with the organic solvents mixture. The Samples were analyzed by direct infusion in a QExactive mass spectrometer (Thermo 18 Scientific) equipped with a TriVersa NanoMate ion source (Advion Biosciences). Samples were 19 analyzed in both positive and negative ion modes with a resolution of Rm/z=200=280000 for MS and 20
Rm/z=200=17500 for MSMS experiments, in a single acquisition. MSMS was triggered by an inclusion 21 list encompassing corresponding MS mass ranges scanned in 1 Da increments. Both MS and MSMS 22 data were combined to monitor CE, DAG and TAG ions as ammonium adducts; PC, PC O-, as acetate 23 adducts; and PE, PE O-and PI as deprotonated anions. MS only was used to monitor LPE as 24 deprotonated anion; Cer, SM and LPC as acetate adducts and cholesterol as ammonium adduct. 25
Data were analyzed with in-house developed lipid identification software based on 1
LipidXplorer.
10, 11 Data post-processing and normalization were performed using an in-house developed 2 data management system. Only lipid identifications with a signal-to-noise ratio >5, and a signal intensity 3 5-fold higher than in corresponding blank samples were considered for further data analysis. 4
Reproducibility was assessed by the inclusion of reference plasma samples (8 reference samples for 5 EUFAM and 3 reference samples for FINRISK) per 96 well plate. Data were corrected for batch and 6 drift effects. Median coefficient of variation was <10% across all batches. 7
A total of 230 lipid species were successfully detected in both the EUFAM and FINRISK 2012 8 cohorts, with detection rates (proportion of samples with successful quantification) between 9.7-100%. 9
Among these, 151 species were detected in at least 80% of both EUFAM and FINRISK samples and 10 were included in the subsequent analyses. The median absolute concentrations of the analyzed lipid 11 species are presented separately for the family and population cohorts in Supplemental Table 5 . 12
SwissLipids names and ID codes are presented for each of the 151 lipid species in Supplemental Table  13 6.
12 Right-skewed lipidomics measures (skewness > 1 in the FINRISK population cohort) were natural 14 logarithm transformed prior to analyses. Values were then normalized using mean and standard 15 deviation values derived from the FINRISK population cohort. Additionally, we calculated weighted 16 class-specific saturation averages for each subject using the following formula: 1*p1 + 2*p2 + … + n*pn 17 (where pn = the concentration of lipid species with n double bonds divided by the total concentration of 18 all species belonging to the class). 19
Genotyping and imputation 20
To assess the association of known genetic lipid loci with the circulating lipid species, we genotyped 21 and imputed the EUFAM and FINRISK samples using several arrays: the HumanCoreExome BeadChip, 22 the Human610-Quad BeadChip, the Affymetrix6.0, and the Infinium HumanOmniExpress (Illumina 23
Inc., San Diego, CA, USA). Genotype calls were generated together with other available data sets using 24 zCall at the Institute for Molecular Medicine Finland (FIMM). After quality control, the samples were 25 phased using SHAPEIT (version 2) 13 and imputed with IMPUTE (version 2.3.1)
14
. We used a combined 26 reference panel based on 1000 Genomes Phase I integrated haplotypes produced using SHAPEIT 1 (version 2) release on June 2014 and an in-house reference panel from 1941 whole genome sequenced 2 Finnish individuals from the FINRISK and Health 2000 population cohorts. 15 We successfully 3 genotyped or imputed 87 lead variants associated with LDL-C and 74 lead variants associated with TGs 4 in published genome-wide association studies.
16-18
5
Statistical analyses 6
To assess the risk of incident coronary artery disease associated with the hyperlipidemias, we used Cox 7 proportional hazards models stratified by sex and excluding individuals with prevalent CAD to estimate 8 hazard ratios (HR) for incident CAD events. We confirmed the validity of Cox proportional hazards 9 assumptions using the cox.zph function in R. 10
We used linear mixed models to estimate the association between lipidomic parameters 11 (concentrations of lipid species or weighted saturation averages) and the other parameter of interest 12 (hyperlipidemia status, continuous lipid measurement, or genotype) as implemented in MMM (version 13
1.01).
19 Transformed lipid species values (or weighted saturation averages) were used as the outcomes, 14 and hyperlipidemia status, age, age 2 , and sex were used as fixed effect covariates. We first assessed both 15 cohorts (the EUFAM family cohort and the FINRISK population cohort) separately, and then together 16 by including an interaction term between cohort and hyperlipidemia status. We examined the 17 independent effects of LDL-C and TG levels by using transformed lipid species as the outcomes and 18 LDL-C, log(TGs), age, age 2 , and sex as fixed effect covariates. Because the lipid species had been 19 quantified in two batches for the EUFAM cohort, we performed all EUFAM analyses separately for 20 both batches, and combined the results using fixed effects inverse-variance weighted meta-analysis as 21 implemented in the R package 'metafor'. P-values were calculated using Wald test. Figure S1 . Overlap of families with family histories of high LDL-C and high TGs. 
HDL-C (mmol/l)
1.4 ± 0. Values are presented as mean ± interquantile range for TGs, BMI, and waist circumference, and mean ± standard deviation for all other variables. A subset of the families fulfilled criteria for both "high LDL-C with family history" and "high TGs with family history" and were thus included in both analysis groups (Supplemental Figure  1 .A.). P-values for between-group comparisons were calculated using Wald test by a linear mixed model correcting for genetic sample relatedness. Sex and age were used as other fixed effect covariates in addition to the group variable except when age was used as the outcome. The risk of incident CAD or CVD was estimated with Cox proportional hazards models similarly to Figure 1 . Additional models included adjustment for selected covariates. Values are presented as mean ± interquantile range for TGs and BMI, and mean ± standard deviation for all other variables. A subset of the families fulfilled criteria for both "high LDL-C with family history" and "high TGs with family history" and were thus included in both analysis groups (Supplemental Figure 1 .B. Effect estimates for having high LDL-C or TG values were derived from linear mixed models with the lipid species as outcomes, and hyperlipidemia status, age, age 2 , and sex as fixed effect covariates. The effect estimates were estimated separately in "high LDL-C" families for high LDL-C status (total n = 463 individuals), in "high TG" families for high TG status (total n = 287 individuals) and in the population for both high LDL-C and high TG status (total n = 897 individuals). To estimate independent associations between the lipid species and LDL-C or TG levels, LDL-C, log(TGs), age, age 2 , and sex were used simultaneously as fixed effect covariates. This analysis was performed separately in the hyperlipidemic families (a); n = 550 individuals) and the FINRISK population cohort (b); n = 897 individuals). An empirical genetic correlation matrix between individuals was used as the covariance structure of a random effect in all models. Lipid species and continuous values of LDL-C and log(TGs) were normalized based on mean and standard deviation values observed in the FINRISK population cohort. P-values were calculated using Wald test and statistical significance was evaluated using the Benjamini-Hochberg method at a 5% false discovery rate. Statistically significant effects are marked with an asterisk (*). 
BMI = Body Mass Index, HDL-C = high-density lipoprotein cholesterol, LDL-C = low-density lipoprotein cholesterol, TGs = triglycerides, TC = total cholesterol.
